Research of Combination Therapy of Western and Traditional Chinese Medicine on Chronic Hepatitis C

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000770

Enrollment

Unknown

Registered

2010-01-17

Start date

2008-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Group A:Binggan Granule 1, 1# bid for 12 months

Group B:Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 2, 1# bid for 12 months

Group C:Binggan Granule 2, 1# bid for 12 months

Group D:Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 1, 1# bid for 12 months

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65, male or female; 2. Meet with the diagnostic standard of chronic hepatitis C; 3. Sign the informed consent 4. HCV-RNA (+); 5. Without contradiction of interferon and Ribavirin.

Exclusion criteria

Exclusion criteria: 1. Complicaed with other hepadnavirus and HIV; 2. With chronic severe hepatitis, decompensated hepatic cirrhosis and liver cancer; 3. Complicated with severe primary diseases of heart, kidney, lung, endocrine system , liver, hematological system, metabolism and gastrointestinal tract, or mental disorder; 4. Pregnant or breast-feeding women; 5. Patients with poor compliance.

Design outcomes

Primary

Measure	Time frame
HCV RNA;Liver biopsy;Ultrasound;Quality of Life of Patients with Chronic Hepatitis;Liver function;TCM scores for signs and syptom;	—

Secondary

Measure	Time frame
Exmaination of HCV;	—

Countries

China

Contacts

Public ContactJianjie Chen

Jianjie_chen@hotmail.com+86 13801872388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 29, 2026